EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

European Journal of Cancer

Volumn 29, Issue 6, 1993, Pages 897-906

  Hendriks, H R ^a   Pizao, P E ^a   Berger, D P ^a   Kooistra, K L ^a   Bibby, M C ^a   Boven, E ^a   Dreef van der Meulen, H C ^a   Henrar, R E C ^a   Fiebig, H H ^a   Double, J A ^a   Hornstra, H W ^a   Pinedo, H M ^a   Workman, P ^a   Schwartsmann, G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; INDOLOQUINONE DERIVATIVE; MITOMYCIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HYPOXIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMAL; ANTINEOPLASTIC AGENTS; AZIRIDINES; BONE MARROW; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMAN; INDOLES; LEUKEMIA P388; MALE; MICE; NEOPLASM TRANSPLANTATION; RATS; TUMOR CELLS, CULTURED;

EID: 0027450014     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(05)80434-4     Document Type: Article

References (40)

1. Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents
2. Preclinical antitumor profile of E09, a novel bioreductive alkylating indoloquinone derivative
3. DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?
4. The role of NAD(P)H: quinone reductase (EC1.6.99.2,DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent E09
5. Bioreductive activation of indoloquinone E09: involvement of DT-diaphorase and DNA crosslinking
6. In vitro activity of the novel indoloquinone EO9 and the influence of pH on cytotoxicity
7. New colorimetric cytotoxicity assay for anticancer-drug screening
8. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
9. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of Mean Graph and COMPARE algorithm
10. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay
11. Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusionassay
12. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development
13. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening
14. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo
15. Some biological characteristics of transplantable lines of mouse adenocarcinomas of the colon
16. Chemotherapy of transplantable adenocarcinomas of the colon in mice. II. Development and characterization of an ascitic line
17. Therapeutic index: a vital component in selection of anticancer agents for clinical trial
18. Influence of site on the chemosensitivity of transplantable murine colon tumors to flavone acetic acid (LM975, NSC347512)
19. In vivo Cancer Models 1976–1982
20. Establishment and characterization of human tumor xenograft models in nude mice
21. Combined in vitro/in vivo test procedure with human tumor xenografts
22. CGP 6809A new nitrosoureido-sugar derivative with activity in human tumor xenografts
23. General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe
24. Analysis and preclinical pharmacology of the novel bioreductive alkylating indoloquinone EO9
25. Pharmacokinetics, distribution and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents
26. The assessment of bioreductive drug toxicity in vitro and in experimental tumours in vivo
27. pH dependance of mitomycin C induced cross linking activity in EMT6 tumour cells
28. Mitomycin antitumour agents: a review of physico-chemical and analytical properties as well as stability.
29. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones
30. In vivo response of mouse adenocarcinoma of the colon (MAC) tumours to indoloquione EO9: correlation with bioreductive enzyme content
31. DT-diaphorase activity correlates with sensitivity to the indoloquinone E09 in mouse and human colon carcinomas
32. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?
33. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cell
34. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.
35. Enzyme-directed bioreductive drug development
36. Bioreductive mechanisms
37. In vitro and in vivo evaluation of the indoloquinone E09 (NSC 382459) against human small cell carcinoma of the lung
38. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9
39. Dualfunction 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas